Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

It's in the genes! Human genetic diversity and the response to anthrax vaccines.

Ingram R, Baillie L.

Expert Rev Vaccines. 2012 Jun;11(6):633-5. doi: 10.1586/erv.12.41. No abstract available.

PMID:
22873120
2.

Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome.

Levinsohn JL, Newman ZL, Hellmich KA, Fattah R, Getz MA, Liu S, Sastalla I, Leppla SH, Moayeri M.

PLoS Pathog. 2012;8(3):e1002638. doi: 10.1371/journal.ppat.1002638.

3.

Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization.

Smith K, Crowe SR, Garman L, Guthridge CJ, Muther JJ, McKee E, Zheng NY, Farris AD, Guthridge JM, Wilson PC, James JA.

Vaccine. 2012 Jun 13;30(28):4276-83. doi: 10.1016/j.vaccine.2012.03.002.

4.

Frequency of epitope-specific naive CD4(+) T cells correlates with immunodominance in the human memory repertoire.

Kwok WW, Tan V, Gillette L, Littell CT, Soltis MA, LaFond RB, Yang J, James EA, DeLong JH.

J Immunol. 2012 Mar 15;188(6):2537-44. doi: 10.4049/jimmunol.1102190.

5.

Human genetic variation altering anthrax toxin sensitivity.

Martchenko M, Candille SI, Tang H, Cohen SN.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2972-7. doi: 10.1073/pnas.1121006109.

6.

HIV vaccine candidates generate in vitro T cell response to putative epitopes in Chinese-origin rhesus macaques.

Liao Q, Strong AJ, Liu Y, Liu Y, Meng P, Fu Y, Touzjian N, Shao Y, Zhao Z, Lu Y.

Vaccine. 2012 Feb 21;30(9):1601-8. doi: 10.1016/j.vaccine.2011.12.117.

PMID:
22261410
7.

Mechanisms of NK cell-macrophage Bacillus anthracis crosstalk: a balance between stimulation by spores and differential disruption by toxins.

Klezovich-Bénard M, Corre JP, Jusforgues-Saklani H, Fiole D, Burjek N, Tournier JN, Goossens PL.

PLoS Pathog. 2012 Jan;8(1):e1002481. doi: 10.1371/journal.ppat.1002481.

8.

Allelic variation on murine chromosome 11 modifies host inflammatory responses and resistance to Bacillus anthracis.

Terra JK, France B, Cote CK, Jenkins A, Bozue JA, Welkos SL, Bhargava R, Ho CL, Mehrabian M, Pan C, Lusis AJ, Davis RC, LeVine SM, Bradley KA.

PLoS Pathog. 2011 Dec;7(12):e1002469. doi: 10.1371/journal.ppat.1002469.

9.

T-cell-inducing vaccines - what's the future.

Gilbert SC.

Immunology. 2012 Jan;135(1):19-26. doi: 10.1111/j.1365-2567.2011.03517.x. Review.

10.

Antibacterial role for natural killer cells in host defense to Bacillus anthracis.

Gonzales CM, Williams CB, Calderon VE, Huante MB, Moen ST, Popov VL, Baze WB, Peterson JW, Endsley JJ.

Infect Immun. 2012 Jan;80(1):234-42. doi: 10.1128/IAI.05439-11.

11.

Regulation of anthrax toxin-specific antibody titers by natural killer T cell-derived IL-4 and IFNγ.

Devera TS, Joshi SK, Aye LM, Lang GA, Ballard JD, Lang ML.

PLoS One. 2011;6(8):e23817. doi: 10.1371/journal.pone.0023817.

12.

Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.

Crowe SR, Garman L, Engler RJ, Farris AD, Ballard JD, Harley JB, James JA.

Vaccine. 2011 May 9;29(20):3670-8. doi: 10.1016/j.vaccine.2011.03.011.

13.

The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.

Brenneman KE, Doganay M, Akmal A, Goldman S, Galloway DR, Mateczun AJ, Cross AS, Baillie LW.

FEMS Immunol Med Microbiol. 2011 Jul;62(2):164-72. doi: 10.1111/j.1574-695X.2011.00800.x.

14.

The adenylate cyclase toxin of Bacillus anthracis is a potent promoter of T(H)17 cell development.

Paccani SR, Benagiano M, Savino MT, Finetti F, Tonello F, D'Elios MM, Baldari CT.

J Allergy Clin Immunol. 2011 Jun;127(6):1635-7. doi: 10.1016/j.jaci.2010.12.1104. No abstract available.

PMID:
21310477
15.

Inflammasome sensor Nlrp1b-dependent resistance to anthrax is mediated by caspase-1, IL-1 signaling and neutrophil recruitment.

Moayeri M, Crown D, Newman ZL, Okugawa S, Eckhaus M, Cataisson C, Liu S, Sastalla I, Leppla SH.

PLoS Pathog. 2010 Dec 9;6(12):e1001222. doi: 10.1371/journal.ppat.1001222.

16.

Differential requirement for Caspase-1 autoproteolysis in pathogen-induced cell death and cytokine processing.

Broz P, von Moltke J, Jones JW, Vance RE, Monack DM.

Cell Host Microbe. 2010 Dec 16;8(6):471-83. doi: 10.1016/j.chom.2010.11.007.

17.

Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults.

Brown BK, Cox J, Gillis A, VanCott TC, Marovich M, Milazzo M, Antonille TS, Wieczorek L, McKee KT Jr, Metcalfe K, Mallory RM, Birx D, Polonis VR, Robb ML.

PLoS One. 2010 Nov 5;5(11):e13849. doi: 10.1371/journal.pone.0013849.

18.

A requirement for FcγR in antibody-mediated bacterial toxin neutralization.

Abboud N, Chow SK, Saylor C, Janda A, Ravetch JV, Scharff MD, Casadevall A.

J Exp Med. 2010 Oct 25;207(11):2395-405. doi: 10.1084/jem.20100995.

19.

Heterodimeric integrin complexes containing beta1-integrin promote internalization and lethality of anthrax toxin.

Martchenko M, Jeong SY, Cohen SN.

Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15583-8. doi: 10.1073/pnas.1010145107.

20.

An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor.

Baillie LW, Huwar TB, Moore S, Mellado-Sanchez G, Rodriguez L, Neeson BN, Flick-Smith HC, Jenner DC, Atkins HS, Ingram RJ, Altmann DM, Nataro JP, Pasetti MF.

Vaccine. 2010 Sep 24;28(41):6740-8. doi: 10.1016/j.vaccine.2010.07.075.

Items per page

Supplemental Content

Support Center